190 related articles for article (PubMed ID: 35896920)
1. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.
Narayan RR; Datta J; Goldman DA; Aveson VG; Walch HS; Sanchez-Vega F; Gönen M; Balachandran VP; Drebin JA; Jarnagin WR; Kingham TP; Wei AC; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg Oncol; 2022 Nov; 29(12):7579-7588. PubMed ID: 35896920
[TBL] [Abstract][Full Text] [Related]
2. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
[TBL] [Abstract][Full Text] [Related]
4. Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Srouji RM; Narayan RR; Boerner T; Buisman FE; Seier K; Gonen M; Balachandran VP; Drebin JA; Jarnagin WR; Kingham TP; Wei A; Kemeny NE; D'Angelica MI
J Surg Oncol; 2020 Dec; 122(8):1536-1542. PubMed ID: 32976666
[TBL] [Abstract][Full Text] [Related]
5. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
6. Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival.
Ecker BL; Shin P; Saadat LV; Court CM; Balachandran VP; Chandwani R; Drebin JA; Jarnagin WR; Kingham TP; Soares KC; Vakiani E; Wei AC; Kemeny NE; Smith JJ; Gonen M; D'Angelica MI
Ann Surg; 2022 Feb; 275(2):371-381. PubMed ID: 34793355
[TBL] [Abstract][Full Text] [Related]
7. Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver-related mortality.
Srouji R; Narayan R; Boerner T; Buisman F; Seier K; Gonen M; Balachandran VP; Drebin J; Jarnagin WR; Kingham TP; Wei A; Kemeny NE; D'Angelica M
J Surg Oncol; 2020 Jun; 121(8):1314-1319. PubMed ID: 32236970
[TBL] [Abstract][Full Text] [Related]
8. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
9. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
12. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
[TBL] [Abstract][Full Text] [Related]
13. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
[TBL] [Abstract][Full Text] [Related]
15. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
[TBL] [Abstract][Full Text] [Related]
16. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
17. The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases.
Buisman FE; Galjart B; van der Stok EP; Kemeny NE; Balachandran VP; Boerner T; Cercek A; Grünhagen DJ; Jarnagin WR; Kingham TP; Verhoef C; Koerkamp BG; D'Angelica MI
HPB (Oxford); 2020 Sep; 22(9):1271-1279. PubMed ID: 31889627
[TBL] [Abstract][Full Text] [Related]
18. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
19. Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study.
Chang W; Chen Y; Zhou S; Ren L; Xu Y; Zhu D; Tang W; Ye Q; Wang X; Fan J; Wei Y; Xu J
Int J Surg; 2023 Oct; 109(10):3070-3077. PubMed ID: 37526097
[TBL] [Abstract][Full Text] [Related]
20. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]